PMID- 35844710
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 2688-6146 (Electronic)
IS  - 2688-6146 (Linking)
VI  - 2
IP  - 3
DP  - 2021 Aug
TI  - Real-world experience: Introduction of T cell replete haploidentical 
      transplantations in a single center.
PG  - 440-448
LID - 10.1002/jha2.203 [doi]
AB  - OBJECTIVES: The aim of this study was to describe real-world data on outcomes of 
      T cell replete haploidentical hematopoietic stem cell transplantation (HSCT) 
      after the introduction of this modality in a single center and to compare them 
      with different donor types. METHOD: Outcomes of 30 consecutive patients with 
      hematological malignancies that received T cell replete haploidentical HSCT with 
      posttransplantation cyclophosphamide (PTCY) from 2016 to 2018 in our center were 
      analyzed and compared to the outcome of human leukocyte antigen (HLA)-related and 
      unrelated matched donor HSCT (n = 97) and to a historical cohort of T cell 
      depleted haploidentical HSCT (n = 11). RESULTS: One year graft-versus-host-free, 
      relapse-free survival in haploidentical HSCT was comparable with other donor 
      types (haplo 40%, matched related donor [MRD] 33%, matched unrelated donor [MUD] 
      25%, p = 0.55). Non relapse mortality was high in haploidentical HSCT (50%), 
      mostly due to infectious complications. However, relapse rates were only 3%, and 
      OS and progression-free survival after 1 year were 47% and thereby also similar 
      to HLA-matched HSCT in our center (MRD 53%, MUD 48%). CONCLUSION: Our data show 
      that T cell replete haploidentical HSCT has similar outcomes to HLA identical 
      HSCT after introduction in our center. More strict adaptation on infection 
      prevention was a crucial aspect of our learning curve. Overall, this type of 
      transplantation is a feasible option when lacking an HLA-identical donor. This 
      option has advantages over an unrelated donor as it brings less logistical 
      challenges than MUD transplantations.
CI  - (c) 2021 The Authors. eJHaem published by British Society for Haematology and John 
      Wiley & Sons Ltd.
FAU - van Gorkom, Gwendolyn
AU  - van Gorkom G
AUID- ORCID: 0000-0001-7327-7834
AD  - Division of Hematology Department of Internal Medicine GROW School for Oncology 
      and Developmental Biology Maastricht University Medical Center Maastricht The 
      Netherlands.
FAU - Billen, Evy
AU  - Billen E
AD  - Division of Hematology Department of Internal Medicine GROW School for Oncology 
      and Developmental Biology Maastricht University Medical Center Maastricht The 
      Netherlands.
FAU - Van Elssen, Catharina
AU  - Van Elssen C
AD  - Division of Hematology Department of Internal Medicine GROW School for Oncology 
      and Developmental Biology Maastricht University Medical Center Maastricht The 
      Netherlands.
FAU - van Gelder, Michel
AU  - van Gelder M
AD  - Division of Hematology Department of Internal Medicine GROW School for Oncology 
      and Developmental Biology Maastricht University Medical Center Maastricht The 
      Netherlands.
FAU - Bos, Gerard
AU  - Bos G
AD  - Division of Hematology Department of Internal Medicine GROW School for Oncology 
      and Developmental Biology Maastricht University Medical Center Maastricht The 
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20210526
PL  - United States
TA  - EJHaem
JT  - EJHaem
JID - 101761942
PMC - PMC9175800
OTO - NOTNLM
OT  - haploidentical
OT  - hematopoietic stem cell transplantation
OT  - posttransplantation cyclophosphamide
COIS- The authors declare no relevant conflict of interest.
EDAT- 2021/05/26 00:00
MHDA- 2021/05/26 00:01
PMCR- 2021/05/26
CRDT- 2022/07/18 03:40
PHST- 2021/03/10 00:00 [received]
PHST- 2021/04/09 00:00 [revised]
PHST- 2021/04/10 00:00 [accepted]
PHST- 2022/07/18 03:40 [entrez]
PHST- 2021/05/26 00:00 [pubmed]
PHST- 2021/05/26 00:01 [medline]
PHST- 2021/05/26 00:00 [pmc-release]
AID - JHA2203 [pii]
AID - 10.1002/jha2.203 [doi]
PST - epublish
SO  - EJHaem. 2021 May 26;2(3):440-448. doi: 10.1002/jha2.203. eCollection 2021 Aug.